Filtered By:
Condition: Heart Attack
Therapy: Dialysis
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 432 results found since Jan 2013.
Mechanisms of Stroke in Patients with Chronic Kidney Disease.
Abstract
BACKGROUND: Given the increasing worldwide prevalence of chronic kidney disease (CKD), it is critical to decrease the associated risk of debilitating vascular complications, including stroke, congestive heart failure, myocardial infarction, and peripheral vascular disease. Treatment options for reducing the risk of all subtypes of stroke in patients with CKD remain limited. For patients with end-stage kidney disease (ESKD), novel applications of noninvasive imaging may help personalize the type of dialysis and dialysis prescription for patients at high-risk.
SUMMARY: This manuscript reviews the heigh...
Source: American Journal of Nephrology - August 27, 2019 Category: Urology & Nephrology Authors: Ghoshal S, Freedman BI Tags: Am J Nephrol Source Type: research
Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
CONCLUSIONS: In patients with anemia of CKD, once-monthly methoxy polyethylene glycol-epoetin beta was noninferior to conventional, shorter-acting erythropoiesis-stimulating agents with respect to rates of major adverse cardiovascular events or all-cause mortality.
PMID: 31420350 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 15, 2019 Category: Urology & Nephrology Authors: Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB Tags: Clin J Am Soc Nephrol Source Type: research
Mediacalcosis in hemodialysis, predictors and prognosis
ConclusionMediacalcosis is a severe complication since it increases the risk of cardiovascular morbidity and mortality in hemodialysis patients, to this end, the individualization of entangled factors involved in its pathophysiology, will slow down or prevent its progression in the future.
Source: Archives of Cardiovascular Diseases Supplements - July 24, 2019 Category: Cardiology Source Type: research
Sternal wound complications in patients undergoing orthotopic heart transplantation
ConclusionSternal wound infections impart a significant burden on patients with OHT. Causative organisms are predominantly virulent gram ‐negative bacteria. Therefore, a high index of suspicion must be maintained for early detection and treatment.
Source: Journal of Cardiac Surgery - February 25, 2019 Category: Cardiovascular & Thoracic Surgery Authors: Tyler J. Wallen,
Andreas Habertheuer,
Jean P. Gottret,
Matthew Kramer,
Zara Abbas,
Mary Siki,
Reilly Hobbs,
Charlie Vasquez,
Maria Molina,
Suhail Kanchwala,
David Low,
Michael Acker,
Prashanth Vallabhajosyula Tags: ORIGINAL ARTICLE Source Type: research
Efficacy and Safety of Ticagrelor Compared with Clopidogrel in Patients with End-Stage Renal Disease with Acute Myocardial Infarction
ConclusionIn patients with ESRD and AMI, ticagrelor resulted in numerically fewer but statistically nonsignificant rates of in-hospital and 1-year cardiovascular events with no significant increase in bleeding events compared with clopidogrel.
Source: American Journal of Cardiovascular Drugs - February 12, 2019 Category: Cardiology Source Type: research
Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD
ConclusionsHigher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD.
Source: American Journal of Kidney Diseases - January 25, 2019 Category: Urology & Nephrology Source Type: research
Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis.
CONCLUSIONS: We found no evidence linking TMAO to adverse clinical outcomes in patients receiving maintenance hemodialysis with moderate to severe secondary hyperparathyroidism.
PMID: 30665924 [PubMed - as supplied by publisher]
Source: Clinical Journal of the American Society of Nephrology : CJASN - January 21, 2019 Category: Urology & Nephrology Authors: Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD Tags: Clin J Am Soc Nephrol Source Type: research
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
ConclusionsDespite initiating dialysis therapy with a higher hemoglobin level, prior treatment with darbepoetin was not associated with a reduction in mortality, myocardial infarction, or heart failure in the first 180 days, but a higher frequency of stroke was observed. In the absence of more definitive data, this may inform decisions regarding the use of erythropoiesis-stimulating agents to treat mild to moderate anemia in patients with type 2 diabetes and chronic kidney disease nearing dialysis therapy initiation.
Source: American Journal of Kidney Diseases - December 19, 2018 Category: Urology & Nephrology Source Type: research
Association of renal arteriosclerosis and hypertension with renal and cardiovascular outcomes in Japanese type 2 diabetic patients with diabetic nephropathy
ConclusionsRenal AS was associated with increasing risks for renal composite events and cardiovascular events in both normal ‐range BP and HT. The risks of renal composite events and cardiovascular events were the highest in both renal AS and HT.This article is protected by copyright. All rights reserved.
Source: Journal of Diabetes Investigation - December 5, 2018 Category: Endocrinology Authors: Miho Shimizu,
Kengo Furuichi,
Tadashi Toyama,
Tomoaki Funamoto,
Shinji Kitajima,
Akinori Hara,
Yasunori Iwata,
Norihiko Sakai,
Toshinari Takamura,
Kiyoki Kitagawa,
Mitsuhiro Yoshimura,
Shuichi Kaneko,
Hitoshi Yokoyama,
Takashi Wada,
Kanazawa Tags: Original Article Source Type: research
Clinical Outcomes of Mitral Valve Reoperations in the United States: An Analysis of the Society of Thoracic Surgeons National Database
ConclusionsDespite a high-risk patient profile, surgical outcomes of reoperative MVS were acceptable, particularly in elective cases with prior mitral valve surgery and without endocarditis.
Source: The Annals of Thoracic Surgery - October 24, 2018 Category: Cardiovascular & Thoracic Surgery Source Type: research
Clinical Outcomes of Mitral Valve Reoperations in the United States: An Analysis of the Society of Thoracic Surgeons National Database.
CONCLUSIONS: Despite a high-risk patient profile, surgical outcomes of reoperative MVS were acceptable, particularly in elective cases with prior mitral valve surgery and without endocarditis.
PMID: 30365952 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - October 23, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Kilic A, Acker MA, Gleason TG, Sultan I, Vemulapalli S, Thibault D, Ailawadi G, Badhwar V, Thourani V, Kilic A Tags: Ann Thorac Surg Source Type: research
Clinical Outcomes of Atherectomy Prior to Percutaneous Coronary Intervention: A Comparative Assessment of Atherectomy in Patients With Obesity (COAP-PCI Subanalysis).
CONCLUSION: In this study assessing atherectomy in obese patients, OA and RA demonstrated comparable outcomes with complication rates within an acceptable range. It demonstrates that OA and RA can be safely performed in this high-risk patient subset with CAC.
PMID: 30318482 [PubMed - as supplied by publisher]
Source: The Journal of Invasive Cardiology - October 16, 2018 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study
Conclusion: Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.Nephron
Source: Nephron - October 5, 2018 Category: Urology & Nephrology Source Type: research
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)
ConclusionThe results from the VERTIS-CV trial will define the CV and renal safety and efficacy of ertugliflozin in patients with T2DM and ASCVD.ClinicalTrials.gov identifier: NCT01986881
Source: American Heart Journal - September 6, 2018 Category: Cardiology Source Type: research
